A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Nivolumab (Primary) ; Hyaluronidase; Nivolumab
- Indications Renal cell carcinoma
- Focus Pharmacokinetics; Registrational
- Acronyms CheckMate-67T
- Sponsors Bristol-Myers Squibb
- 21 Jun 2024 According to a Bristol Myers Squibb media release, the EMA has validated the extension application of subcutaneous nivolumab given as solution for injection in a new strength (600 mg/vial) across multiple previously approved adult solid tumor indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab combination therapy, or in combination with chemotherapy or cabozantinib, based on the results from the Phase 3 CheckMate -67T study.
- 04 Jun 2024 Results of an exploratory analysis assessing health-related quality of life measured using patient-reported outcomes (PROs), FKSI-19 (kidney cancer-related HRQoL) and the EQ-5D-5L (patient's health status) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 23 May 2024 According to Bristol Myers Squibb media release, the company announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress.